{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:01:37Z","timestamp":1781373697616,"version":"3.54.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>In chronic kidney disease (CKD), plasma uric acid levels are increased because of the decrease in glomerular filtration rate. However, in addition to CKD, hyperuricemia is frequently associated with a number of other conditions such as hypertension, type 2 diabetes, obesity, and heart failure, overweight, and cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>It is now becoming increasingly clear that, in many clinical conditions, elevated levels of uric acid have a much greater role beyond just causing gout. The present review will summarize current knowledge on the relation between hyperuricemia, CKD, and existing comorbidities, as well as the mechanisms of uric acid\u2013related renal damage. In addition, the role and evidence for urate-lowering therapy in prevention and cardiovascular protection in CKD patients is discussed with a focus on allopurinol and febuxostat. To date, several clinical studies have provided evidence that urate-lowering therapy may help to prevent and delay the decline of renal function in patients with CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Use of a xanthine oxidase inhibitor should be considered in patients who are at high renal risk and\/or with declining renal function in the presence of hyperuricemia with and without deposition, although additional studies are warranted to define treatment targets. Notwithstanding, the possibility to delay deterioration of renal function in patients with CKD merits consideration.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11906-020-01116-3","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T03:02:39Z","timestamp":1604113359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection"],"prefix":"10.1007","volume":"22","author":[{"given":"Jan T.","family":"Kielstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"issue":"1","key":"1116_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","volume":"131","author":"BF Culleton","year":"1999","unstructured":"Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7\u201313. https:\/\/doi.org\/10.7326\/0003-4819-131-1-199907060-00003.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1116_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","volume":"10","author":"P Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654\u201361. https:\/\/doi.org\/10.1038\/nrrheum.2014.124.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1116_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.ackd.2012.05.004","volume":"19","author":"K Nashar","year":"2012","unstructured":"Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012;19(6):386\u201391. https:\/\/doi.org\/10.1053\/j.ackd.2012.05.004.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"1116_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1681\/ASN.2008101115","volume":"21","author":"OW Moe","year":"2010","unstructured":"\u2022 Moe OW. Posing the question again: does chronic uric acid nephropathy exist? J Am Soc Nephrol. 2010;21(3):395\u20137. https:\/\/doi.org\/10.1681\/ASN.2008101115. An interesting review of how uric acid could affect renal function.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1116_CR5","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341. https:\/\/doi.org\/10.1002\/art.30520.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1116_CR6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","volume":"72","author":"G Trifiro","year":"2013","unstructured":"Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694\u2013700. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201254.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1116_CR7","first-page":"1295","volume":"18","author":"G Desideri","year":"2014","unstructured":"Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014;18(9):1295\u2013306.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"1116_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ndt\/gfu352","volume":"30","author":"J Jing","year":"2015","unstructured":"Jing J, Kielstein JT, Schultheiss UT, Sitter T, Titze SI, Schaeffner ES, et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. 2015;30(4):613\u201321. https:\/\/doi.org\/10.1093\/ndt\/gfu352.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1116_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jare.2017.05.001","volume":"8","author":"T Eleftheriadis","year":"2017","unstructured":"Eleftheriadis T, Golphinopoulos S, Pissas G, Stefanidis I. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial. J Adv Res. 2017;8(5):555\u201360. https:\/\/doi.org\/10.1016\/j.jare.2017.05.001.","journal-title":"J Adv Res"},{"issue":"6","key":"1116_CR10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204\u201311. https:\/\/doi.org\/10.1681\/ASN.2007101075.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1116_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056546","volume":"8","author":"SP Juraschek","year":"2013","unstructured":"Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One. 2013;8(2):e56546. https:\/\/doi.org\/10.1371\/journal.pone.0056546.","journal-title":"PLoS One"},{"key":"1116_CR12","doi-asserted-by":"publisher","unstructured":"Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342\u201350. https:\/\/doi.org\/10.1001\/archinternmed.2008.605.","DOI":"10.1001\/archinternmed.2008.605"},{"issue":"2","key":"1116_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239\u201347. https:\/\/doi.org\/10.1053\/j.ajkd.2007.05.013.","journal-title":"Am J Kidney Dis"},{"key":"1116_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. https:\/\/doi.org\/10.1186\/1471-2369-15-122.","journal-title":"BMC Nephrol"},{"issue":"1","key":"1116_CR15","doi-asserted-by":"publisher","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","volume":"12","author":"CW Tsai","year":"2017","unstructured":"Tsai CW, Lin SY, Kuo CC, Huang CC. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017;12(1):e0170393. https:\/\/doi.org\/10.1371\/journal.pone.0170393.","journal-title":"PLoS One"},{"issue":"2","key":"1116_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ndt\/gfx297","volume":"33","author":"CW Tsai","year":"2018","unstructured":"Tsai CW, Chiu HT, Huang HC, Ting IW, Yeh HC, Kuo CC. Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. Nephrol Dial Transplant. 2018;33(2):231\u201341. https:\/\/doi.org\/10.1093\/ndt\/gfx297.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1116_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40620-014-0158-9","volume":"28","author":"YC Chou","year":"2015","unstructured":"Chou YC, Kuan JC, Yang T, Chou WY, Hsieh PC, Bai CH, et al. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol. 2015;28(4):457\u201362. https:\/\/doi.org\/10.1007\/s40620-014-0158-9.","journal-title":"J Nephrol"},{"issue":"2","key":"1116_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","volume":"56","author":"G Bellomo","year":"2010","unstructured":"Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264\u201372. https:\/\/doi.org\/10.1053\/j.ajkd.2010.01.019.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1116_CR19","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407\u201313. https:\/\/doi.org\/10.1681\/ASN.2008010080.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1116_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","volume":"8","author":"UAA Sharaf El Din","year":"2017","unstructured":"Sharaf El Din UAA, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8(5):537\u201348. https:\/\/doi.org\/10.1016\/j.jare.2016.11.004.","journal-title":"J Adv Res"},{"issue":"3","key":"1116_CR21","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","volume":"71","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71(3):362\u201370. https:\/\/doi.org\/10.1053\/j.ajkd.2017.08.017.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"1116_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.exger.2008.01.006","volume":"43","author":"G Sturm","year":"2008","unstructured":"Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F, Group MS. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The mild to moderate kidney disease (MMKD) study. Exp Gerontol. 2008;43(4):347\u201352. https:\/\/doi.org\/10.1016\/j.exger.2008.01.006.","journal-title":"Exp Gerontol"},{"issue":"5","key":"1116_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796\u2013803. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.021.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1116_CR24","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2215\/CJN.03140315","volume":"10","author":"S De Cosmo","year":"2015","unstructured":"De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(11):1921\u20139. https:\/\/doi.org\/10.2215\/CJN.03140315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1116_CR25","doi-asserted-by":"publisher","unstructured":"Kaewput W, Thongprayoon C, Chewcharat A, Rangsin R, Satirapoj B, Kaewput C, et al. Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: a nationwide retrospective cohort study. Ther Apher Dial. 2020. https:\/\/doi.org\/10.1111\/1744-9987.13480.","DOI":"10.1111\/1744-9987.13480"},{"issue":"9","key":"1116_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.metabol.2016.05.009","volume":"65","author":"X Xia","year":"2016","unstructured":"Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F. Serum uric acid and mortality in chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2016;65(9):1326\u201341. https:\/\/doi.org\/10.1016\/j.metabol.2016.05.009.","journal-title":"Metabolism."},{"issue":"12","key":"1116_CR27","doi-asserted-by":"publisher","first-page":"e114259","DOI":"10.1371\/journal.pone.0114259","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. https:\/\/doi.org\/10.1371\/journal.pone.0114259.","journal-title":"PLoS One"},{"key":"1116_CR28","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.2147\/DMSO.S222570","volume":"12","author":"L Gaita","year":"2019","unstructured":"Gaita L, Timar R, Lupascu N, Roman D, Albai A, Potre O, et al. The impact of Hyperuricemia on cardiometabolic risk factors in patients with diabetes mellitus: a cross-sectional study. Diabetes Metab Syndr Obes. 2019;12:2003\u201310. https:\/\/doi.org\/10.2147\/DMSO.S222570.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"1116_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.diabet.2019.03.001","volume":"45","author":"MY Chen","year":"2019","unstructured":"Chen MY, Wang AP, Wang JW, Ke JF, Yu TP, Li LX, et al. Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes. Diabetes Metab. 2019;45(6):557\u201363. https:\/\/doi.org\/10.1016\/j.diabet.2019.03.001.","journal-title":"Diabetes Metab"},{"issue":"6","key":"1116_CR30","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","volume":"21","author":"CJ Bailey","year":"2019","unstructured":"Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291\u20138. https:\/\/doi.org\/10.1111\/dom.13670.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1116_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrneph.2016.159","volume":"12","author":"K Hahn","year":"2016","unstructured":"Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12(12):711\u20132. https:\/\/doi.org\/10.1038\/nrneph.2016.159.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"1116_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.sjbs.2018.11.013","volume":"26","author":"Y Xin","year":"2019","unstructured":"Xin Y, Guo Y, Li Y, Ma Y, Li L, Jiang H. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis. Saudi J Biol Sci. 2019;26(2):421\u20136. https:\/\/doi.org\/10.1016\/j.sjbs.2018.11.013.","journal-title":"Saudi J Biol Sci"},{"key":"1116_CR33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.12659\/AOT.896821","volume":"21","author":"N Pagonas","year":"2016","unstructured":"Pagonas N, Kor S, Seibert FS, Giese A, Zidek W, Reinke P, et al. Effects of treatment of asymptomatic hyperuricemia on graft survival and mortality in kidney transplant recipients. Ann Transplant. 2016;21:350\u20139. https:\/\/doi.org\/10.12659\/AOT.896821.","journal-title":"Ann Transplant"},{"issue":"3","key":"1116_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.transproceed.2017.01.006","volume":"49","author":"S Eyupoglu","year":"2017","unstructured":"Eyupoglu S, Eyupoglu D, Kendi-Celebi Z, Akturk S, Tuzuner A, Keven K, et al. Risk factors of hyperuricemia after renal transplantation and its long-term effects on graft functions. Transplant Proc. 2017;49(3):505\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2017.01.006.","journal-title":"Transplant Proc"},{"issue":"12","key":"1116_CR35","doi-asserted-by":"publisher","first-page":"e0209156","DOI":"10.1371\/journal.pone.0209156","volume":"13","author":"DG Kim","year":"2018","unstructured":"Kim DG, Choi HY, Kim HY, Lee EJ, Huh KH, Kim MS, et al. Association between post-transplant serum uric acid levels and kidney transplantation outcomes. PLoS One. 2018;13(12):e0209156. https:\/\/doi.org\/10.1371\/journal.pone.0209156.","journal-title":"PLoS One"},{"issue":"6","key":"1116_CR36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.transproceed.2018.02.127","volume":"50","author":"M Magott-Procelewska","year":"2018","unstructured":"Magott-Procelewska M, Madziarska K, Boratynska M, Chudoba P, Lepiesza A, Mazanowska O, et al. Kidney transplantation from old deceased donors: impact of uric acid level-a quarter-century of experience in one transplant center. Transplant Proc. 2018;50(6):1701\u20134. https:\/\/doi.org\/10.1016\/j.transproceed.2018.02.127.","journal-title":"Transplant Proc"},{"issue":"2","key":"1116_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jcpt.12794","volume":"44","author":"X Shen","year":"2019","unstructured":"Shen X, Li J, Fu Q, Liu L, Gao X, Chen X, et al. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia. J Clin Pharm Ther. 2019;44(2):318\u201326. https:\/\/doi.org\/10.1111\/jcpt.12794.","journal-title":"J Clin Pharm Ther"},{"issue":"13","key":"1116_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5414\/CNP88FX17","volume":"88","author":"T Petreski","year":"2017","unstructured":"Petreski T, Bevc S, Ekart R, Hojs R. Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis. Clin Nephrol. 2017;88(13):69\u201372. https:\/\/doi.org\/10.5414\/CNP88FX17.","journal-title":"Clin Nephrol"},{"issue":"9","key":"1116_CR39","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221\u20138. https:\/\/doi.org\/10.1093\/ndt\/gft029.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1116_CR40","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","volume":"41","author":"RJ Johnson","year":"2003","unstructured":"\u2022\u2022 Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183\u201390. https:\/\/doi.org\/10.1161\/01.HYP.0000069700.62727.C5. This article presents the leading hypothesis and the mechanisms that may link uric acid to hypertension and kideny diseases.","journal-title":"Hypertension"},{"issue":"5","key":"1116_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/0002-9343(75)90222-3","volume":"59","author":"L Berger","year":"1975","unstructured":"Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59(5):605\u201313. https:\/\/doi.org\/10.1016\/0002-9343(75)90222-3.","journal-title":"Am J Med"},{"issue":"12","key":"1116_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","volume":"15","author":"Y Sato","year":"2019","unstructured":"Sato Y, Feig DI, Stack AG, Kang DH, Lanaspa MA, Ejaz AA, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15(12):767\u201375. https:\/\/doi.org\/10.1038\/s41581-019-0174-z.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"1116_CR43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jpeds.2012.12.078","volume":"162","author":"DI Feig","year":"2013","unstructured":"Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. J Pediatr. 2013;162(5):896\u2013902. https:\/\/doi.org\/10.1016\/j.jpeds.2012.12.078.","journal-title":"J Pediatr"},{"issue":"5","key":"1116_CR44","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101\u20136. https:\/\/doi.org\/10.1161\/hy1101.092839.","journal-title":"Hypertension."},{"issue":"5","key":"1116_CR45","doi-asserted-by":"publisher","first-page":"F1105","DOI":"10.1152\/ajprenal.00170.2002","volume":"283","author":"LG Sanchez-Lozada","year":"2002","unstructured":"Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Ren Physiol. 2002;283(5):F1105\u201310. https:\/\/doi.org\/10.1152\/ajprenal.00170.2002.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"3","key":"1116_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000368507","volume":"40","author":"H Uedono","year":"2015","unstructured":"Uedono H, Tsuda A, Ishimura E, Yasumoto M, Ichii M, Ochi A, et al. Relationship between serum uric acid levels and intrarenal hemodynamic parameters. Kidney Blood Press Res. 2015;40(3):315\u201322. https:\/\/doi.org\/10.1159\/000368507.","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"1116_CR47","doi-asserted-by":"publisher","first-page":"C584","DOI":"10.1152\/ajpcell.00600.2006","volume":"293","author":"YY Sautin","year":"2007","unstructured":"Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative\/nitrosative stress. Am J Phys Cell Phys. 2007;293(2):C584\u201396. https:\/\/doi.org\/10.1152\/ajpcell.00600.2006.","journal-title":"Am J Phys Cell Phys"},{"issue":"6","key":"1116_CR48","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","volume":"28","author":"MA Yu","year":"2010","unstructured":"Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234\u201342.","journal-title":"J Hypertens"},{"issue":"11","key":"1116_CR49","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"AK So","year":"2017","unstructured":"So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639\u201347. https:\/\/doi.org\/10.1038\/nrrheum.2017.155.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1116_CR50","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1093\/ndt\/gfv024","volume":"31","author":"Y Isaka","year":"2016","unstructured":"Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2016;31(6):890\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfv024.","journal-title":"Nephrol Dial Transplant"},{"key":"1116_CR51","doi-asserted-by":"publisher","first-page":"8603164","DOI":"10.1155\/2016\/8603164","volume":"2016","author":"A Kushiyama","year":"2016","unstructured":"Kushiyama A, Nakatsu Y, Matsunaga Y, Yamamotoya T, Mori K, Ueda K, et al. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic Steatohepatitis. Mediat Inflamm. 2016;2016:8603164\u201315. https:\/\/doi.org\/10.1155\/2016\/8603164.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"1116_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3967\/bes2018.013","volume":"31","author":"D Cheng","year":"2018","unstructured":"Cheng D, Du R, Wu XY, Lin L, Peng K, Ma LN, et al. Serum uric acid is associated with the predicted risk of prevalent cardiovascular disease in a community-dwelling population without diabetes. Biomed Environ Sci. 2018;31(2):106\u201314. https:\/\/doi.org\/10.3967\/bes2018.013.","journal-title":"Biomed Environ Sci"},{"issue":"2","key":"1116_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40292-018-0250-7","volume":"25","author":"G Desideri","year":"2018","unstructured":"Desideri G, Virdis A, Casiglia E, Borghi C. Working Group on Uric A, Cardiovascular Risk of the Italian Society of H. Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, a study protocol for a retrospective observational study. High Blood Press Cardiovasc Prev. 2018;25(2):197\u2013202. https:\/\/doi.org\/10.1007\/s40292-018-0250-7.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"1116_CR54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","volume":"484","author":"G Ndrepepa","year":"2018","unstructured":"Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150\u201363. https:\/\/doi.org\/10.1016\/j.cca.2018.05.046.","journal-title":"Clin Chim Acta"},{"issue":"4","key":"1116_CR55","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/2047487313519346","volume":"22","author":"SK Zalawadiya","year":"2015","unstructured":"Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, Bavishi C, Lunagaria A, Kottam A, et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015;22(4):513\u20138. https:\/\/doi.org\/10.1177\/2047487313519346.","journal-title":"Eur J Prev Cardiol"},{"key":"1116_CR56","doi-asserted-by":"publisher","unstructured":"\u2022 Kielstein JT, Heisterkamp M, Jing J, Nadal J, Schmid M, F. K, et al. Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. Clin Kidney J. 2019:sfz136. https:\/\/doi.org\/10.1093\/ckj\/sfz136. An interesting survey of the use of urate-lowering therapies in CKD patients.","DOI":"10.1093\/ckj\/sfz136"},{"key":"1116_CR57","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40620-020-00702-7","volume":"33","author":"B Bonino","year":"2020","unstructured":"Bonino B, Leoncini G, Russo E, Pontremoli R, Viazzi F. Uric acid in CKD: has the jury come to the verdict? J Nephrol. 2020;33:715\u201324. https:\/\/doi.org\/10.1007\/s40620-020-00702-7.","journal-title":"J Nephrol"},{"key":"1116_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000484275","volume":"192","author":"A Trevino-Becerra","year":"2018","unstructured":"Trevino-Becerra A. Uric acid: the unknown uremic toxin. Contrib Nephrol. 2018;192:25\u201333. https:\/\/doi.org\/10.1159\/000484275.","journal-title":"Contrib Nephrol"},{"issue":"1","key":"1116_CR59","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1038\/s41598-019-43241-3","volume":"9","author":"TR Oh","year":"2019","unstructured":"Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, Sung SA, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019;9(1):6681. https:\/\/doi.org\/10.1038\/s41598-019-43241-3.","journal-title":"Sci Rep"},{"issue":"11","key":"1116_CR60","doi-asserted-by":"publisher","first-page":"e0187550","DOI":"10.1371\/journal.pone.0187550","volume":"12","author":"X Su","year":"2017","unstructured":"Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: a meta-analysis. PLoS One. 2017;12(11):e0187550. https:\/\/doi.org\/10.1371\/journal.pone.0187550.","journal-title":"PLoS One"},{"issue":"8","key":"1116_CR61","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"\u2022\u2022 Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388\u201393. https:\/\/doi.org\/10.2215\/CJN.01580210. One of the clinical studies demonstrating that allopurinol slows down the progression of kidney diseases and may provide cardiovascular protection.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1116_CR62","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ndt\/gft378","volume":"29","author":"B Bose","year":"2014","unstructured":"Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406\u201313. https:\/\/doi.org\/10.1093\/ndt\/gft378.","journal-title":"Nephrol Dial Transplant"},{"key":"1116_CR63","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","volume":"16","author":"T Kanji","year":"2015","unstructured":"Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. https:\/\/doi.org\/10.1186\/s12882-015-0047-z.","journal-title":"BMC Nephrol"},{"issue":"29","key":"1116_CR64","doi-asserted-by":"publisher","first-page":"e16311","DOI":"10.1097\/MD.0000000000016311","volume":"98","author":"TC Lin","year":"2019","unstructured":"\u2022 Lin TC, Hung LY, Chen YC, Lo WC, Lin CH, Tam KW, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(29):e16311. https:\/\/doi.org\/10.1097\/MD.0000000000016311. The meta-analysis suggesting that, other than its urate-lowering effect, febuxostat presented a reno-protective effect in CKD patients.","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"1116_CR65","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","volume":"40","author":"S Kojima","year":"2019","unstructured":"Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, et al. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J. 2019;40(22):1778\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehz119.","journal-title":"Eur Heart J"},{"issue":"3","key":"1116_CR66","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-018-2051-2","volume":"51","author":"JW Lee","year":"2019","unstructured":"Lee JW, Lee KH. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol. 2019;51(3):467\u201373. https:\/\/doi.org\/10.1007\/s11255-018-2051-2.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"1116_CR67","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1007\/s11255-019-02318-8","volume":"51","author":"X Zhang","year":"2019","unstructured":"Zhang X, Wan D, Yang G, Peng Q, Wang X. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia. Int Urol Nephrol. 2019;51(12):2273\u201383. https:\/\/doi.org\/10.1007\/s11255-019-02318-8.","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"1116_CR68","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5414\/CP203466","volume":"58","author":"AY Yang","year":"2020","unstructured":"Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther. 2020;58(1):21\u20138. https:\/\/doi.org\/10.5414\/CP203466.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"1116_CR69","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/cpt.1697","volume":"107","author":"YO Hsu","year":"2020","unstructured":"\u2022 Hsu YO, Wu IW, Chang SH, Lee CC, Tsai CY, Lin CY, et al. Comparative renoprotective effect of febuxostat and allopurinol in predialysis stage 5 chronic kidney disease patients: a nationwide database analysis. Clin Pharmacol Ther. 2020;107(5):1159\u201369. https:\/\/doi.org\/10.1002\/cpt.1697. A study showing a lower risk of progression to dialysis in predialysis stage 5 CKD patients using febuxostat.","journal-title":"Clin Pharmacol Ther"},{"key":"1116_CR70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijcard.2015.08.110","volume":"213","author":"AH Wu","year":"2016","unstructured":"Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.110.","journal-title":"Int J Cardiol"},{"issue":"33","key":"1116_CR71","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"1","key":"1116_CR72","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-018-1143-7","volume":"20","author":"Q Luo","year":"2019","unstructured":"Luo Q, Xia X, Li B, Lin Z, Yu X, Huang F. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2019;20(1):18. https:\/\/doi.org\/10.1186\/s12882-018-1143-7.","journal-title":"BMC Nephrol"},{"issue":"26","key":"1116_CR73","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"\u2022 Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa1916624. A study which does not confirm the benefits of allopurinol in patients with type 1 diabetes.","journal-title":"N Engl J Med"},{"issue":"26","key":"1116_CR74","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"\u2022\u2022 Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1915833. A randomized controlled trial failing to demonstrate a positive effect of allopurinol on kidney disease progression.","journal-title":"N Engl J Med"},{"issue":"8","key":"1116_CR75","doi-asserted-by":"publisher","first-page":"e026677","DOI":"10.1136\/bmjopen-2018-026677","volume":"9","author":"Q Li","year":"2019","unstructured":"Li Q, Li X, Wang J, Liu H, Kwong JS, Chen H, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019;9(8):e026677. https:\/\/doi.org\/10.1136\/bmjopen-2018-026677.","journal-title":"BMJ Open"},{"issue":"10","key":"1116_CR76","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.39254","volume":"67","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2015;67(10):2557\u201368. https:\/\/doi.org\/10.1002\/art.39254.","journal-title":"Arthritis Rheum"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-01116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-020-01116-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-020-01116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T14:13:50Z","timestamp":1618150430000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-020-01116-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":76,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1007\/s11906-020-01116-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"14 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"JK has received research funding from ExThera Medical, Infectopharm, and has received speaker fees from Vifor, ExThera Medical, Amgen; stock of ChemoCentryx.RP has received consulting and speaker fees from Menarini International.MB has received consulting and speaker fees from Menarini International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"102"}}